C4 Therapeutics is set to advance clinical development of cemsidomide, with Phase 1 data expected in late 2025 for multiple myeloma and non-Hodgkin’s lymphoma.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.